We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532318

CAS#: 152831-36-2

Description: NE10790, also known as 3-PEHPC, is a Rab geranylgeranyl transferase inhibitor. NE10790 is a risedronate analog, which belongs to the group of phosphonocarboxylates in which one of the phosphonate groups is substituted by a carboxyl group. NE-10790 had strongly reduced binding affinity, but still retained some antiresorptive activity. The group of phosphonocarboxylates, with strongly reduced bone affinity, provides an interesting therapeutic option.

Price and Availability

Size Price Shipping out time Quantity
25mg USD 250 2 Weeks
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 1950 2 Weeks
1g USD 2950 2 Weeks
2g USD 5250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-09-28. Prices are subject to change without notice.

NE10790 is in stock

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 532318
Name: NE10790
CAS#: 152831-36-2
Chemical Formula: C8H10NO6P
Exact Mass: 247.0246
Molecular Weight: 247.14
Elemental Analysis: C, 38.88; H, 4.08; N, 5.67; O, 38.84; P, 12.53

Synonym: NE10790; NE 10790; NE-10790; 3-PEHPC;

IUPAC/Chemical Name: 2-hydroxy-2-phosphono-3-(pyridin-3-yl)propanoic acid


InChi Code: InChI=1S/C8H10NO6P/c10-7(11)8(12,16(13,14)15)4-6-2-1-3-9-5-6/h1-3,5,12H,4H2,(H,10,11)(H2,13,14,15)

SMILES Code: O=C(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Zhou X, Born EJ, Allen C, Holstein SA, Wiemer DF. N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation. Bioorg Med Chem Lett. 2015 Jun 1;25(11):2331-4. doi: 10.1016/j.bmcl.2015.04.021. Epub 2015 Apr 17. PubMed PMID: 25935643; PubMed Central PMCID: PMC4462192.

2: Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, Lai ZW, Miklossy G, Singh RR, Chudakov DM, Malorni W, Middleton F, Banki K, Perl A. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis. 2014 Oct;73(10):1888-97. doi: 10.1136/annrheumdis-2013-203794. Epub 2013 Jul 29. PubMed PMID: 23897774; PubMed Central PMCID: PMC4047212.

3: Roelofs AJ, Stewart CA, Sun S, Błażewska KM, Kashemirov BA, McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res. 2012 Apr;27(4):835-47. doi: 10.1002/jbmr.1543. PubMed PMID: 22228189.

4: Stein W, Schrepfer S, Itoh S, Kimura N, Velotta J, Palmer O, Bartos J, Wang X, Robbins RC, Fischbein MP. Prevention of transplant coronary artery disease by prenylation inhibitors. J Heart Lung Transplant. 2011 Jul;30(7):761-9. doi: 10.1016/j.healun.2011.01.720. Epub 2011 Mar 31. PubMed PMID: 21458297.

5: Coxon FP, Taylor A, Stewart CA, Baron R, Seabra MC, Ebetino FH, Rogers MJ. The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates. Bone. 2011 Jul;49(1):111-21. doi: 10.1016/j.bone.2011.03.686. Epub 2011 Mar 21. PubMed PMID: 21419243.

6: Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone. 2011 Feb;48(2):259-66. doi: 10.1016/j.bone.2010.09.035. Epub 2010 Oct 20. PubMed PMID: 20920623.

7: Virtanen SS, Sandholm J, Yegutkin G, Kalervo Väänänen H, Härkönen PL. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells. Cell Biol Int. 2010 Aug;34(8):815-26. doi: 10.1042/CBI20090288. PubMed PMID: 20446922.

8: Hald A, Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, Ebetino FH, Kassem M, Heegaard AM. Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. Int J Cancer. 2009 Sep 1;125(5):1177-85. doi: 10.1002/ijc.24436. PubMed PMID: 19444917.

9: Baron RA, Tavaré R, Figueiredo AC, Błazewska KM, Kashemirov BA, McKenna CE, Ebetino FH, Taylor A, Rogers MJ, Coxon FP, Seabra MC. Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem. 2009 Mar 13;284(11):6861-8. doi: 10.1074/jbc.M806952200. Epub 2008 Dec 11. PubMed PMID: 19074143; PubMed Central PMCID: PMC2652301.

10: Fournier PG, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH, Clézardin P. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res. 2008 Nov 1;68(21):8945-53. doi: 10.1158/0008-5472.CAN-08-2195. PubMed PMID: 18974139.

11: Lawson MA, Coulton L, Ebetino FH, Vanderkerken K, Croucher PI. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochem Biophys Res Commun. 2008 Dec 12;377(2):453-457. doi: 10.1016/j.bbrc.2008.09.157. Epub 2008 Oct 16. PubMed PMID: 18929536.

12: Marma MS, Xia Z, Stewart C, Coxon F, Dunford JE, Baron R, Kashemirov BA, Ebetino FH, Triffitt JT, Russell RG, McKenna CE. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem. 2007 Nov 29;50(24):5967-75. Epub 2007 Nov 2. PubMed PMID: 17975902.

13: Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006 Jun;6(3):307-12. Epub 2006 May 2. Review. PubMed PMID: 16650801.

14: Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Horton MA, Seabra MC, Ebetino FH, Rogers MJ. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem. 2001 Dec 21;276(51):48213-22. Epub 2001 Oct 1. PubMed PMID: 11581260.

15: Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000 Jun 1;60(11):2949-54. PubMed PMID: 10850442.

16: van Beek ER, Löwik CW, Ebetino FH, Papapoulos SE. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone. 1998 Nov;23(5):437-42. PubMed PMID: 9823450.